Cargando…
Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
BACKGROUND: Temsavir (TMR), the active agent of the gp120-directed attachment inhibitor fostemsavir (FTR), the CD4-directed attachment inhibitor ibalizumab (IBA), and the CCR5 antagonist maraviroc (MVC) are antiretroviral agents that target steps in HIV-1 viral entry. Although mechanisms of inhibiti...
Autores principales: | Rose, Ronald, Gartland, Margaret, Li, Zhufang, Zhou, Nannan, Cockett, Mark, Beloor, Jagadish, Lataillade, Max, Ackerman, Peter, Krystal, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654283/ https://www.ncbi.nlm.nih.gov/pubmed/34628442 http://dx.doi.org/10.1097/QAD.0000000000003097 |
Ejemplares similares
-
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database
por: Gartland, Margaret, et al.
Publicado: (2021) -
Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(®) Entry assay
por: Gartland, Margaret, et al.
Publicado: (2020) -
Ibalizumab: First Global Approval
por: Markham, Anthony
Publicado: (2018) -
Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment
por: Sevinsky, Heather, et al.
Publicado: (2017) -
Correction to: Ibalizumab: First Global Approval
por: Markham, Anthony
Publicado: (2018)